Literature DB >> 8290659

Central serotonergic changes following antidepressant treatment: a neuroendocrine assessment.

M E Leatherman1, R D Ekstrom, M Corrigan, S W Carson, G Mason, R N Golden.   

Abstract

We employed a neuroendocrine challenge paradigm to study the effects of antidepressant treatment on serotonergic systems in depressed patients. We compared the maximum prolactin response to intravenous clomipramine (CMI) in depressed patients who responded to antidepressant treatment to that of nonresponders. Pretreatment baseline prolactin concentrations and pretreatment prolactin responses to clomipramine challenge were not different in responders compared to non-responders. However, following antidepressant treatment, the 6 responders demonstrated a significant change in their clomipramine challenge test results, as indicated by an increase in prolactin responses. In contrast, the 7 nonresponders did not demonstrate a change in their prolactin response to clomipramine challenge following treatment. These data support the hypothesis that serotonergic system dysfunction, as manifested by blunted prolactin response to clomipramine challenge, tends to normalize after successful treatment for depression, and that abnormal serotonergic function may be a state-dependent characteristic.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8290659

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  2 in total

1.  Breast cancer recurrence risk in relation to antidepressant use after diagnosis.

Authors:  Jessica Chubak; Diana S M Buist; Denise M Boudreau; Mary Anne Rossing; Thomas Lumley; Noel S Weiss
Journal:  Breast Cancer Res Treat       Date:  2007-12-06       Impact factor: 4.872

2.  Antidepressant medications and change in mammographic density in postmenopausal women.

Authors:  Jessica Chubak; Erin J A Bowles; Mary Beth Terry; Amy Trentham-Dietz; Diana S M Buist
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-03       Impact factor: 4.254

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.